A A AText only | Accessibility | Privacy and cookies

Browse site A to Z

Search results

Go To Advanced Search

You could also try: marks (231), results (1000)

Criteria-for-BRCA1-and-BRCA2-testing

Description
Wessex Clinical Genetics Service, G Level, Mailpoint 627, Princess Anne Hospital, Coxford Road, Southampton SO16 5YA Tel: 023 8120 6170 Website
Url
/Media/UHS-website-2019/Docs/Services/Genetics/Cancer-genetics/criteria-for-brca1-and-brca2-testing.doc

Carboplatin (AUC5)-Pegylated Liposomal Doxorubicin (Caelyx)x)

Description
Chemotherapy Protocol GYNAECOLOGICAL CANCER CARBOPLATIN (AUC5) - DOXORUBICIN PEGYLATED LIPOSOMAL (Caelyx) Please note this protocol is based on information for the use
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Ovarian-cancer/CarboplatinAUC5-Pegylated-Liposomal-DoxorubicinCaelyxVer1.pdf

Vinorelbine (oral day 1, 8 and 15)

Description
Chemotherapy Protocol LUNG CANCER – NON-SMALL CELL (NSCLC) VINORELBINE (Oral) (Day 1, 8, 15) This protocol may require funding Regimen NSCLC
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lung-cancer-non-small-cellNSCLC/Vinorelbineoralday18and15ver11.pdf

Vinorelbine (oral day 1 and 8)

Description
Chemotherapy Protocol LUNG CANCER – NON-SMALL CELL (NSCLC) VINORELBINE (Oral) (Day 1 and 8) This protocol may require funding Regimen NSCLC
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lung-cancer-non-small-cellNSCLC/Vinorelbineoralday1and8ver11.pdf

Tivozanib

Description
Chemotherapy Protocol RENAL CELL Regimen TIVOZANIB • Renal Cell - Tivozanib Indication • Patients with a confirmed histological diagnosis of renal cell carcinoma with
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Renal-cell/Tivozanib.pdf

RGCVP-Cyclophosphamide-Gemcitabine-Prednisolone-Rituximab-Vincristine Ver 1.2

Description
Chemotherapy Protocol LYMPHOMA CYCLOPHOSPHAMIDE-GEMCITABINE-PREDNISOLONE-RITUXIMAB-VINCRISTINE (RGCVP) Regimen L
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lymphoma/RGCVP-Cyclophosphamide-Gemcitabine-Prednisolone-Rituximab-Vincristine-Ver-1.2.pdf

MyelomaCTDa28CyclophosphamideDexamethasoneThalidomideAttenuated(CTDa)Ver1

Description
Chemotherapy Protocol MULTIPLE MYELOMA CTDa (28)-CYCLOPHOSPHAMIDE-DEXAMETHASONE-THALIDOMIDE (ATTENUATED) (CTDa-28) There are multiple versions of this protocol in use
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Myeloma/MyelomaCTDa28CyclophosphamideDexamethasoneThalidomideAttenuatedCTDaVer1.pdf

MyelomaCTD21CyclophosphamideDexamethasoneThalidomide(CTD)Ver1

Description
Chemotherapy Protocol MULTIPLE MYELOMA CTD (21)-CYCLOPHOSPHAMIDE-DEXAMETHASONE-THALIDOMIDE (21 days) There are multiple versions of this protocol in use. Please
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Myeloma/MyelomaCTD21CyclophosphamideDexamethasoneThalidomideCTDVer1.pdf

Cyclophosphamide-Docetaxel-Doxorubicin Ver 1.1

Description
Chemotherapy Protocol BREAST CANCER CYCLOPHOSPHAMIDE-DOCETAXEL-DOXORUBICIN Regimen (TAC) Breast Cancer – Cyclophosphamide-Docetaxel-Doxorubicin (TAC) Indication Adjuvant therapy for node positive
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Breastcancer/BreastCyclophosphamideDocetaxelDoxorubicinTACVer11.pdf

IdelalisibRituximab

Description
Chemotherapy Protocol Chronic Lymphocytic Leukaemia (CLL) Idelalisib-Rituximab Regimen • CLL – Idelalisib-Rituximab Indication • Chronic lymphocytic leukaemia in adults when the disease
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/CLL/IdelalisibRituximab.pdf
281 to 290 of 548
Previous … 27 28 29 30 31 … Next